Trabectedin (ET-743, Yondelis™) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype

Investigational New Drugs

Volumn 25, Issue 1, 2007, Pages 1-7

  Beumer, Jan Hendrik ^a   Buckle, Tessa ^b   Ouwehand, Mariet ^b   Franke, Niels E F ^b   Lopez Lazaro, Luis ^c   Schellens, Jan H M ^b,d   Beijnen, Jos H ^a,d   Van Tellingen, Olaf ^b,e  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c PHARMAMAR S A   (Spain)

^d UTRECHT UNIVERSITY   (Netherlands)

^e NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBON 14; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; TRABECTEDIN; VALSPODAR; ZOSUQUIDAR;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOG; DRUG ACCUMULATION; DRUG DISPOSITION; DRUG EFFECT; DRUG MECHANISM; DRUG UPTAKE; ISOTOPE LABELING; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SWINE;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BIOLOGICAL TRANSPORT; CARBON RADIOISOTOPES; CELL LINE; CELL MEMBRANE PERMEABILITY; CELL SURVIVAL; DIBENZOCYCLOHEPTENES; DIOXOLES; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; INHIBITORY CONCENTRATION 50; INTRACELLULAR FLUID; LLC-PK1 CELLS; MEMBRANE TRANSPORT PROTEINS; MICE; P-GLYCOPROTEIN; PACLITAXEL; QUINOLINES; SWINE; TETRAHYDROISOQUINOLINES; TRANSFECTION;

EID: 33750445585     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-006-7773-9     Document Type: Article

References (31)

1. Blay JY, Le Cesne A, Verweij J, Scurr M, Seynaeve C, Bonvalot S, Hogendoorn P, Jimeno J, Evrard V, Van Glabbeke M, Judson I (2004) A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours. Eur J Cancer 40:1327-1331
2. Garcia-Carbonero R, Supko JG, Manola J, Seiden MV, Harmon D, Ryan DP, Quigley MT, Merriam P, Canniff J, Goss G, Matulonis U, Maki RG, Lopez T, Puchalski TA, Sancho MA, Gomez J, Guzman C, Jimeno J, Demetri GD (2004) Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 22:1480-1490
3. Laverdiere C, Kolb EA, Supko JG, Gorlick R, Meyers PA, Maki RG, Wexler L, Demetri GD, Healey JH, Huvos AG, Goorin AM, Bagatell R, Ruiz-Casado A, Guzman C, Jimeno J, Harmon D (2003) Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer 98:832-840
4. Ryan DP, Puchalski T, Supko JG, Harmon D, Maki R, Garcia-Carbonero R, Kuhlman C, Winkelman J, Merriam P, Quigley T, Jimeno J, Manola J, Demetri GD (2002) A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors. Oncologist 7:531-538
5. van Kesteren C, de Vooght MM, Lopez-Lazaro L, Mathot RA, Schellens JHM, Jimeno JM, Beijnen JH (2003) Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin. Anticancer Drugs 14:487-502
6. Amador ML, Jimeno J, Paz-Ares L, Cortes-Funes H, Hidalgo M (2003) Progress in the development and acquisition of anticancer agents from marine sources. Ann Oncol 14:1607-1615
7. Moore BM, Seaman FC, Wheelhouse RT, Hurley LH (1998) Mechanism for the catalytic activation of ecteinscidin 743 and its subsequent alkylation of guanine N2. J Am Chem Soc 120:2490-2491
8. Pommier Y, Kohlhagen G, Bailly C, Waring M, Mazumder A, Kohn KW (1996) DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 35:13303-13309
9. Kanzaki A, Takebayashi Y, Ren XQ, Miyashita H, Mori S, Akiyama S, Pommier Y (2002) Overcoming multidrug drug resistance in P-glycoprotein/MDR1- overexpressing cell lines by ecteinascidin 743. Mol Cancer Ther 1:1327-1334
10. Minuzzo M, Marchini S, Broggini M, Faircloth G, D'Incalci M, Mantovani R (2000) Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci USA 97:6780-6784
11. Jin S, Gorfajn B, Faircloth G, Scotto KW (2000) Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc Natl Acad Sci USA 97:6775-6779
12. Synold TW, Dussault I, Forman BM (2001) The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 7:584-590
13. Allen JD, Brinkhuis RF, van Deemter L, Wijnholds J, Schinkel AH (2000) Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance. Cancer Res 60:5761-5766
14. Fromm MF (2003) Importance of P-glycoprotein for drug disposition in humans. Eur J Clin Invest 33 (Suppl 2):6-9
15. Lin JH, Yamazaki M (2003) Role of p-glycoprotein in pharmacokinetics: Clinical implications. Clin Pharmacokinet 42:59-98
16. Sun J, He ZG, Cheng G, Wang SJ, Hao XH, Zou MJ (2004) Multidrug resistance P-glycoprotein: crucial significance in drug disposition and interaction. Med Sci Monit 10:RA5-RA14
17. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ, van der Valk MA, Voordouw AC, Spits H, van Tellingen O, Zijlmans JM, Fibbe WE, Borst P (1997) Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 94:4028-4033
18. Erba E, Bergamaschi D, Bassano L, Ronzoni S, Di Liberti G, Muradore I, Vignati S, Faircloth G, Jimeno J, D'Incalci M (2000) Isolation and characterization of an IGROV-1 human ovarian cancer cell line made resistant to Ecteinascidin-743 (ET-743). Br J Cancer 82:1732-1739
19. Takahashi N, Li W, Banerjee D, Guan Y, Wada-Takahashi Y, Brennan MF, Chou TC, Scotto KW, Bertino JR (2002) Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo. Cancer Res 62:6909-6915
20. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63
21. Schinkel AH, Wagenaar E, Mol CA, van Deemter L (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97:2517-2524
22. Marchini S, Marrazzo E, Bonomi R, Chiorino G, Zaffaroni M, Weissbach L, Hornicek FJ, Broggini M, Faircloth GT, D'Incalci M (2005) Molecular characterisation of two human cancer cell lines selected in vitro for their chemotherapeutic drug resistance to ET-743. Eur J Cancer 41:323-333
23. Noonan KE, Beck C, Holzmayer TA, Chin JE, Wunder JS, Andrulis IL, Gazdar AF, Willman CL, Griffith B, Von Hoff DD (1990) Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 87:7160-7164
24. Sanfilippo O, Ronchini E, De Marco C, Di Fronzo G, Silvestrini R (1991) Expression of P-glycoprotein in breast cancer tissue and in vitro resistance to doxorubicin and vincristine. Eur J Cancer 27:155-158
25. Futscher BW, Blake LL, Gerlach JH, Grogan TM, Dalton WS (1993) Quantitative polymerase chain reaction analysis of mdr1 mRNA in multiple myeloma cell lines and clinical specimens. Anal Biochem 213:414-421
26. Keith WN, Stallard S, Brown N (1990) Expression of mdr1 and gst-π in human breast tumours: comparison to in vitro chemosensitivity. Br J Cancer 61:712-716
27. Illmer T, Schaich M, Oelschlagel U, Nowak R, Renner U, Ziegs B, Subat S, Neubauer A, Ehninger G (1999) A new PCR MIMIC strategy to quantify low mdr1 mRNA levels in drug resistant cell lines and AML blast samples. Leuk Res 23:653-663
28. Mechetner E, Kyshtoobayeva A, Zonis S, Kim H, Stroup R, Garcia R, Parker RJ, Fruehauf JP (1998) Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res 4:389-398
29. Dexter DW, Reddy RK, Geles KG, Bansal S, Myint MA, Rogakto A, Leighton JC, Goldstein LJ (1998) Quantitative reverse transcriptase-polymerase chain reaction measured expression of MDR1 and MRP in primary breast carcinoma. Clin Cancer Res 4:1533-1542
30. Schinkel AH (1999) P-Glycoprotein, a gatekeeper in the bloodbrain barrier. Adv Drug Deliv Rev 36:179-194
31. Lin JH, Yamazaki M (2003) Role of P-glycoprotein in pharmacokinetics: Clinical implications. Clin Pharmacokinet 42:59-98